http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200132109-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4aaf127397fd5f114d8bfee1628e155e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70582 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2881 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56966 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-7233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2884 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-72 |
| filingDate | 2019-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3dc538fa8a2303599e70337b92c30191 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10be1d2c6e664c9e7a55ffa3f4ee2f4b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce1c2bb1754c44a3d7c1fa25b0558d57 |
| publicationDate | 2020-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20200132109-A |
| titleOfInvention | A method for characterizing cancer stem cell specific proteome and antibody in cell membrane and a use thereof |
| abstract | In the present invention, a) biopanning is performed on a cancer stem cell line by a phage display technique, and a pool of phage antibodies secured for each round is expressed by biopanning, and then the binding force to cancer stem cells and normal cells is analyzed. , b) Isolating a single colony from the antibody pool and analyzing the binding force of each monoclonal antibody to a cancer stem cell line to select a monoclonal antibody that specifically binds only to cancer cell lines without binding to normal cells, c) The selected antibody is produced in the form of a scFv-fixed region (Fc) antibody that functions similar to whole IgG in a phage-single chain variable segment (scFv), and d) IgG or the scFv- in cancer stem cells and cancer cells. After the antibody-binding reaction is carried out with the Fc antibody, the supernatant is separated after obtaining cancer stem cells and cancer cell lysate, and the separated supernatant is pulled down and purified cell surface protein-antibody. The conjugate is isolated and the obtained cell surface protein-antibody conjugate sample is analyzed to identify specific cancer stem cell membrane proteins recognized by the cancer stem cell antibody. It relates to a method for simultaneously detecting a druggable target protein. |
| priorityDate | 2019-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 240.